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Introduction
To achieve full T-cell activation and recognition with the major histocompatibility complex (MHC) class I/II on antigen presenting cells (APC) by the T cell receptor, a second signal is required [1, 2] . This is provided by antigen-independent interactions between cosignaling molecules on T cells and their respective ligands on antigen presenting cells or APC [1, 2] .
Costimulatory molecules including CD40-CD154 and CD80-CD28 interactions, play a prominent role in the initiation of immune responses [2, 3] . Monocytes as APC, express the CD40 and CD80 molecules [1] [2] [3] . Of importance, both antigens are either undetected or detected at low levels in most human acute myeloid leukemia (AML) blasts [4] [5] [6] [7] [8] . Moreover, very low levels of CD80 are observed on circulating monocytes from children with various cancers [9] and on monocytes infiltrating colorectal carcinomas [10] . This deficient expression of CD40 and CD80 reflects an ineffective antigen-presenting function of these cells. Yet, AML cells transfected with the CD80 gene are capable of enhancing T cell effector function [11] [12] [13] . As an alternative approach, human CD80 immunoglobulin G (IgG) fusion protein targeted to the high-affinity Fc- receptor (CD64) expressed on AML blasts has been used to restore its expression on these cells, thereby enhancing their immunogenicity for autologous T cells [14] . Therefore, understanding the molecular mechanisms involved in the upregulation of cosignaling molecules may be helpful in order to stimulate T cell-mediated immunity.
The interferon (IFN) family includes type I () and type II () IFNs that are implicated in the resistance of mammalian hosts to pathogens and in the modulation of antiviral, antitumoral and immune responses [15] . The efficacy of IFNs has been exploited in maintenance therapy for patients with cancer and viral related diseases [16, 17] . Type I and type II IFNs, by respectively binding type I and type II IFN-receptors, activate both similar 4 and dissimilar Jak/Stat signal pathways [18] [19] [20] . IFN-- stimulation leads to the formation of two transcriptional activator complexes, a homodimer of signal transducer and activator of transcription (Stat)1 and IFN-stimulated gene factor 3 (ISGF3) which comprises Stat1, Stat2
and IRF-9 (or p48) [21] . Stat1 homodimer binds IFN--activated site (GAS) motifs in promoter regions of various genes, such as interferon regulatory factor-1 (IRF-1) gene [20, 21] . ISGF3 binds to IFN-stimulated response element (ISRE) promoter regions in ISREcontaining genes, including IRF-7 gene, and activates their transcription [21] . IFN- signals mainly through Stat1 homodimer [20, 21] . In addition, IFN- and IFN- may exhibit separate bioactivities through their different affinities and rate constants of interaction with IFN type I receptor subunits [22, 23] .
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Materials and Methods
Reagents and antibodies
Ficoll-Hypaque was from GE Healthcare France (Aulnay-sous-Bois, France). RPMI 1640 medium, L-glutamine, sodium pyruvate and fetal calf serum (FCS) (lipopolysaccharide levels < 0.1 ng/mL) were from Gibco (Paisley, Scotland 
Cells isolation and cultures
Primary monocytes from normal blood donors were isolated by Ficoll-Hypaque density gradient (1.077 g/mL) centrifugation and adherence as described [32] . As assessed by flow cytometry analysis of the CD14 antigen, adherent cells contained ≥95 % monocytes.
Mononuclear cells from AML patients were isolated on Ficoll-Hypaque gradient in the same way as described above for primary monocytes. After counting, the isolated cells were directly processed and plated at a density of 1x10 6 /mL in RPMI 1640 medium supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 40 g/mL gentamycin containing 10% FCS.
These cells were cultured at 37°C for for various periods of time in a 5 % CO 2 humidified atmosphere, in the absence or presence of varying concentrations of IFNs.
U937 cell line and IRF-1 siRNA transfection
The monocytic cell line U937 obtained from American Tissue Cell Culture (Manassas, VA, USA) was grown in RPMI 1640 medium supplemented with glutamine, sodium pyruvate, gentamycin and 5% FCS at 37°C. Cells (2x10 5 /mL) were cultured in the absence or presence of IFNs (1000 U/mL) for 24 h. For transfection, U937 cells (1x10 6 ) in 100 l solution kit V were transfected with 50 nM IRF-1 small interfering RNA (siRNA) or with negative control siRNA using an Amaxa nucleofector according to the manufacturer's protocol (program U13). Cells were then plated in 6-well plates for 18 h, followed by stimulation with IFN- (500 U/mL) for additional 18 h. Cells were then harvested, immunostained with anti-CD80
and analyzed for CD80 expression by flow cytometry. 
RT-PCR analysis
RNA extraction and cDNA synthesis were conducted as described [33] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 8 was controlled by measuring the  2 -microglobulin transcripts. The NIH Image 1.63 software was used for the analysis and the quantification of the bands after acquisition in an Appligen densitometer (Oncor).
Immunoblot analysis
Total cell extracts were prepared, separated on 12% polyacrylamide-SDS gels, transferred to nitrocellulose (Schleicher & Schuell France) and blotted [37] with Abs for IRF-1 (rabbit polyclonal IgG), IRF-7 (rabbit polyclonal IgG) or actin (mIgG1) as described previously [37] using the chemiluminescence technique developed by Santa Cruz. Immunoreactive protein bands were detected by autoradiography on Hyperfilms (Kodak) and the bands were acquired with an Appligen densitometer (Oncor).
Enzyme-linked immunosorbent assays
The culture supernatant fractions from cells (10 6 cells/mL) cultured for 3 days in the absence or presence of IFNs were harvested under sterile conditions and frozen before CD80 and MMP-9 contents were determined using commercial ELISA kits respectively provided by
Bender MedSystems (Vienna, Austria) and R&D (Abingdon, UK). Controls included FCSsupplemented RPMI 1640 medium alone incubated under the same conditions. The concentrations were calculated after substraction of the control values. Detection level was 0.1 ng/mL for CD80 and 1 ng/mL for MMP-9.
Data analysis
Results from n independent experiments were analyzed for statistical significant differences using the Student's t-test. They are expressed as the mean ± SD. P values below 0.01 were considered as statistically significant. 
3.Results
Type I and II IFNs upregulate surface CD80 expression on monocytes
As assessed by immunostaining and flow cytometry, freshly isolated monocytes cultured in medium alone for 18 h expressed low levels of CD80 surface protein ( Figure 1A ). Exposure Figure 2B ). These data also indicate that roughly similar doseresponses and kinetics were observed for both type I and type II IFNs.
To investigate whether the enhancement of surface CD80 was associated with the release of soluble CD80, we measured CD80 protein in monocyte supernatants by ELISA. No detectable levels of CD80 were found (data not shown), suggesting that surface CD80 upregulation was not accompanied by CD80 release to the extracellular compartment.
Concomitant upregulation of cell surface CD40 and CD80 by IFNs
IFN- and IFN- were previously shown to upregulate the cosignaling molecule CD40 on monocytes [24, 25] . We analyzed the simultaneous expression of CD40 and CD80 on monocytes, before and after IFNs treatment, by two-color direct immunofluorescence. Figure 3 shows one representative case in which unstimulated monocytes (control) co-expressed CD40 and CD80 at low levels (25%), and IFNs stimulation resulted in the appearance of a predominant CD40 + CD80 + subpopulation (around 70 %), suggesting that both molecules are regulated by IFNs in a coordinate way.
IFN-mediated regulation of CD80 mRNA transcription
We then investigated whether the IFN-driven increase in CD80 expression was at the 
IFN-, but not IFN , upregulates CD80 in U937 cells through IRF-1 activation
In order to confirm this role of IRF-1 in CD80 expression, similar experiments were performed with the U937 cell line. The latter monocytic cell line is negative for CD40 but expresses CD80 [42, 43] . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12
Upregulation of CD80 on monocytes is not mediated by TNF 
The possibility that TNF- could upregulate CD80 expression in monocytes was then investigated. In contrast to a previous report [31] , no stimulatory effect of exogenously added TNF- on CD80 expression was detected; the addition of TNF- was also unable to potentiate the effect of IFN- (Table 1 ). We next tested the possible implication of TNF- endogenously released by monocytes in the basal expression of CD80. Monocytes were incubated for 18 h with neutralizing TNF- antibody or with control goat IgG. As a control of TNF- action, matrix metalloproteinase-9 (MMP-9) production was analysed in parallel.
While MMP-9 production was inhibited in the presence of anti-TNF-, but not of goat IgG as isotype control, the levels of CD80 expression were not modified (Table 1) . Together, these data strongly suggest that CD80 expression does not require TNF- signalling and indicate that NF-b signalling is unlikely to be involved.
Differential upregulation of CD80 in AML cells according to FAB subtype
We investigated the effects of IFNs on CD80 expression in leukemic cells from 12 AML patients. Two groups of patients could be classified according to the spontaneous expression of CD80 on the leukemic cells and their modulation by IFNs. The first group (n=7) of "non responders" is characterized by a weak basal level of CD80 (MFI < 20) and an absence of upregulation by IFN-. The second group (n=5) of "responders" display significant expression of CD80 (MFI >20) that markedly increases following IFN- treatment ( Figure 6A ). IFN- - were also capable of enhancing CD80 expression in these "responders", albeit to a lower degree (not shown). Of importance, the "non responders" group included all FAB-M1/M2 patients and only one M5 patient. In contrast, the "responders" group included FAB-M4/M5 M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13 patients and no M1/M2 patients. These subtypes of AML are defined by their distinct morphologic features : M1 and M2 represent respectively undifferentiated and differentiated myeloblastic leukemia ; M4 and M5 myelomonocytic and monocytic variants.When regrouped in M1/M2 on one hand and M4/M5 on the other hand, a significant difference in the repartition between "non responders" and "responders" was revealed ( Table 2) . As observed for normal monocytes, IFNs were capable of coinducing CD40 and CD80 surface expression, as exemplified for one representative M5 patient whose cells were stimulated with IFN- ( Figure 6B ).
We also examined CD80, IRF-1 and IRF-7 transcripts in "responders" and "non responders".
As shown for one M5 responder, IRF-1, but not IRF-7 transcript was induced by IFN- treatment and also, albeit to a lesser degree, by IFN- ( Figure 7A ); these inductions of IRF-1
were paralleled with that of CD80, inasmuch as upregulations of the CD80 transcript ( Figure   7A ) and cell surface protein ( Figure 7B ) were observed. In contrast, both types of IFNs were unable to stimulate IRF-1 and CD80 transcription in one representative case of a FAB/M1 patient ( Figure 7A ), even though type I IFN triggered IRF-7 expression, as in normal monocytes. Together, these results further emphasize that the increased CD80 surface expression by IFNs is associated with IRF-1 activation in AML cells. by IFNs could have a detrimental effect on leukemic cells.
4.Discussion
In conclusion, this study emphasizes the role of IRF-1 in the upregulation of CD40 and CD80 costimulatory molecules on normal and tumoral monocytes, and may help in the development of novel therapeutic strategies eliciting specific T cell responses to leukemia-associated antigens. Monitoring ex vivo the expression of CD80 on AML blasts and its modulation by IFNs could be of great interest to predict the patients who would be the more susceptible to benefit from such treatments.
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+ CD80 + cells is indicated respectively in the lower right, upper left and upper right quadrants of each plot.
Figure 4. Effects of IFNs on CD80, IRFs, CD40 and VEGF transcripts in monocytes
The cDNAs from a representative monocyte sample cultured for 18 h with or without 1000 U/mL of the various IFNs were used as templates for PCR reactions using specific primers for CD80, IRF-1, IRF-7, CD40, VEGF or 2-microglobulin (internal standard), as described in Materials and Methods. PCR products were run on 2% agarose gels. The intensity of the bands of the various transcripts were compared using the the NIH Image 1.63 software after acquisition in an Appligen densitometer (Oncor) and normalised with 2-microglobulin.
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